Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Valentine Delore"'
Autor:
Bruno Guy, Fernando Noriega, R. Leon Ochiai, Maïna L’azou, Valentine Delore, Anna Skipetrova, François Verdier, Laurent Coudeville, Stephen Savarino, Nicholas Jackson
Publikováno v:
Expert Review of Vaccines, Vol 16, Iss 7, Pp 671-684 (2017)
Introduction: Dengue is an important and still growing public health problem associated with substantial morbidity, as well as significant social and economic impact. The present review describes the main features and development of the first dengue
Externí odkaz:
https://doaj.org/article/1ec8f753909b486bb2894b85ecb0c2bb
Autor:
Beatriz P. Quiambao, Jonathan G. Lim, Valerie Bosch Castells, Christele Augard, Celine Petit, Catherine Bravo, Valentine Delore, Guy Houillon
Publikováno v:
Vaccine. 40(36)
Shorter rabies pre-exposure prophylaxis (PrEP) regimens may offer improved convenience and feasibility over classic 3-week regimens, for example in regions with poor access to vaccines or for travelers to rabies-endemic regions. In this multicenter,
Autor:
Valentine Delore, Laurent Coudeville, Maïna L’Azou, Stephen Savarino, R. Leon Ochiai, Bruno Guy, Nicholas Jackson, Anna Skipetrova, François Verdier, Fernando Noriega
Publikováno v:
Expert Review of Vaccines. 16:671-684
Dengue is an important and still growing public health problem associated with substantial morbidity, as well as significant social and economic impact. The present review describes the main features and development of the first dengue vaccine (CYD-T
Autor:
Alexandre Servat, Jean Lang, Charles Lutsch, Keith Veitch, Valentine Delore, Florence Cliquet
Publikováno v:
Vaccine. 22:244-249
In a recently published Syrian hamster animal challenge study [Vaccine 19 (2001) 2273], a highly purified, heat-treated equine rabies immunoglobulin (pERIG HT, Favirab™) did not elicit satisfactory protection. The efficacies of this batch, a second
Autor:
Stephanie Pepin, Valentine Delore, Grenville Marsh, Pierre Saliou, Sabine Arnoux, Camille Salamand
Publikováno v:
Vaccine. 24(10)
Safety data on the inactivated split influenza vaccine, Vaxigrip®, were compiled and analysed from 28 clinical trials (total: 4599 subjects aged 6 months to 99 years) to provide a robust estimate of the reactogenicity profile. The most frequent soli